Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized Study of BAY 43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.

X
Trial Profile

A Phase III Randomized Study of BAY 43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms TARGET
  • Sponsors Bayer
  • Most Recent Events

    • 01 Feb 2022 Results from TARGET study and four (CALGB/Alliance) clinical trials identifying predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach published in the Pharmacogenomics Journal
    • 08 Jun 2021 Results of an analysis assessing genetic predictors of sorafenib-induced toxicities from two clinical studies: ALLIANCE and TARGET presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 11 Oct 2016 Results assessing genetic basis of sorafenib toxicity presented at the 41st European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top